Cargando…

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients

Soluble BCMA (sBCMA) levels are elevated in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the association between sBCMA levels and prognosis in MGUS and SMM has not been studied. We retrospectively analyzed sBCMA levels in stored samples fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Visram, A., Soof, C., Rajkumar, S. V., Kumar, S. K., Bujarski, S., Spektor, T. M., Kyle, R. A., Berenson, J. R., Dispenzieri, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225625/
https://www.ncbi.nlm.nih.gov/pubmed/34168119
http://dx.doi.org/10.1038/s41408-021-00505-4
_version_ 1783712123826733056
author Visram, A.
Soof, C.
Rajkumar, S. V.
Kumar, S. K.
Bujarski, S.
Spektor, T. M.
Kyle, R. A.
Berenson, J. R.
Dispenzieri, A.
author_facet Visram, A.
Soof, C.
Rajkumar, S. V.
Kumar, S. K.
Bujarski, S.
Spektor, T. M.
Kyle, R. A.
Berenson, J. R.
Dispenzieri, A.
author_sort Visram, A.
collection PubMed
description Soluble BCMA (sBCMA) levels are elevated in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the association between sBCMA levels and prognosis in MGUS and SMM has not been studied. We retrospectively analyzed sBCMA levels in stored samples from 99 MGUS and 184 SMM patients. Baseline sBCMA levels were significantly higher in MGUS and SMM patients progressing to MM during clinical follow up. When stratified according to the median baseline sBCMA level for each cohort, higher levels were associated with a shorter PFS for MGUS (HR 3.44 comparing sBCMA ≥77 vs <77 ng/mL [95% CI 2.07–5.73, p < 0.001] and SMM (HR 2.0 comparing sBCMA ≥128 vs <128 ng/mL, 95% 1.45–2.76, p < 0.001) patients. The effect of sBCMA on PFS was similar even after adjusting for the baseline MGUS or SMM risk stratification. We evaluated paired serum samples and found that sBCMA increased significantly in MGUS and SMM patients who eventually progressed to MM, whereas among MGUS non-progressors the sBCMA level remained stable. While our results require independent validation, they suggest that sBCMA may be a useful biomarker to identify MGUS and SMM patients at increased risk of progression to MM independent of the established risk models.
format Online
Article
Text
id pubmed-8225625
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82256252021-07-09 Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients Visram, A. Soof, C. Rajkumar, S. V. Kumar, S. K. Bujarski, S. Spektor, T. M. Kyle, R. A. Berenson, J. R. Dispenzieri, A. Blood Cancer J Article Soluble BCMA (sBCMA) levels are elevated in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the association between sBCMA levels and prognosis in MGUS and SMM has not been studied. We retrospectively analyzed sBCMA levels in stored samples from 99 MGUS and 184 SMM patients. Baseline sBCMA levels were significantly higher in MGUS and SMM patients progressing to MM during clinical follow up. When stratified according to the median baseline sBCMA level for each cohort, higher levels were associated with a shorter PFS for MGUS (HR 3.44 comparing sBCMA ≥77 vs <77 ng/mL [95% CI 2.07–5.73, p < 0.001] and SMM (HR 2.0 comparing sBCMA ≥128 vs <128 ng/mL, 95% 1.45–2.76, p < 0.001) patients. The effect of sBCMA on PFS was similar even after adjusting for the baseline MGUS or SMM risk stratification. We evaluated paired serum samples and found that sBCMA increased significantly in MGUS and SMM patients who eventually progressed to MM, whereas among MGUS non-progressors the sBCMA level remained stable. While our results require independent validation, they suggest that sBCMA may be a useful biomarker to identify MGUS and SMM patients at increased risk of progression to MM independent of the established risk models. Nature Publishing Group UK 2021-06-24 /pmc/articles/PMC8225625/ /pubmed/34168119 http://dx.doi.org/10.1038/s41408-021-00505-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Visram, A.
Soof, C.
Rajkumar, S. V.
Kumar, S. K.
Bujarski, S.
Spektor, T. M.
Kyle, R. A.
Berenson, J. R.
Dispenzieri, A.
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
title Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
title_full Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
title_fullStr Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
title_full_unstemmed Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
title_short Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
title_sort serum bcma levels predict outcomes in mgus and smoldering myeloma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225625/
https://www.ncbi.nlm.nih.gov/pubmed/34168119
http://dx.doi.org/10.1038/s41408-021-00505-4
work_keys_str_mv AT visrama serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT soofc serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT rajkumarsv serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT kumarsk serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT bujarskis serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT spektortm serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT kylera serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT berensonjr serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients
AT dispenzieria serumbcmalevelspredictoutcomesinmgusandsmolderingmyelomapatients